Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Oct 11:2022:8807957.
doi: 10.1155/2022/8807957. eCollection 2022.

Severe Bradycardia Leading to Hemodynamic Instability Associated with Remdesivir Use in a Patient with COVID-19 Pneumonia

Bhargavi Donepudi  1 , Shikhar Agarwal  2 , Lokendra Thakur  1
Affiliations
Case Reports

Severe Bradycardia Leading to Hemodynamic Instability Associated with Remdesivir Use in a Patient with COVID-19 Pneumonia

Bhargavi Donepudi et al. Case Rep Crit Care. .

Abstract

Remdesivir (RDV) is an approved treatment for hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. There is limited literature on the cardiac adverse effects of RDV. We report a case of a patient who developed hemodynamically unstable bradycardia after the initiation of RDV that resolved after discontinuing RDV.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Figures

Figure 1
Figure 1
Normal ECG at the time of admission.
Figure 2
Figure 2
Telemetry strips showing bradycardia after the initiation of RDV (day one).
Figure 3
Figure 3
Telemetry strips showing bradycardia after the initiation of RDV (day two).
Figure 4
Figure 4
Telemetry strips showing bradycardia after the initiation of RDV (day four).
See this image and copyright information in PMC

References

    1. Beigel J. H., Tomashek K. M., Dodd L. E., et al. Remdesivir for the treatment of Covid-19 — final report. The New England Journal of Medicine . 2020;383(19):1813–1826. doi: 10.1056/NEJMoa2007764. - DOI - PMC - PubMed
    1. WHO Solidarity Trial Consortium. Repurposed antiviral drugs for Covid-19 — interim WHO solidarity trial results. The New England Journal of Medicine . 2021;384(6):497–511. doi: 10.1056/NEJMoa2023184. - DOI - PMC - PubMed
    1. Ader F., Bouscambert-Duchamp M., Hites M., et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. The Lancet Infectious Diseases . 2022;22(2):209–221. doi: 10.1016/S1473-3099(21)00485-0. - DOI - PMC - PubMed
    1. Gubitosa J. C., Kakar P., Gerula C., et al. Marked sinus bradycardia associated with remdesivir in COVID-19: a case and literature review. Case Reports . 2020;2(14):2260–2264. doi: 10.1016/j.jaccas.2020.08.025. - DOI - PMC - PubMed
    1. Ching P. R., Lee C. Remdesivir-associated bradycardia. BMJ Case Reports . 2021;14(9, article e245289) doi: 10.1136/bcr-2021-245289. - DOI - PMC - PubMed

Publication types

LinkOut - more resources